In a randomized prospective study, patients using erlotinib with concurrent thoracic radiotherapy had significantly longer PFS than those receiving standard CRT among patients with EGFR‐mutant LA‐NSCLC.25 The gene discussed is EGFR; the disease is non-small cell lung carcinoma.